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Kinetics of procainamide and N-acetylprocainamide in renal
failure. Four normal subjects and four functionally anephric
patients were given 6.5 mg/kg of body wt of procainamide
hydrochloride iv., and plasma concentrations of procainamide(PA) and its major active metabolite N-acetylprocainamide
(NAPA) were measured. Two individuals in each group were fast
isonicotinic acid hydrazide (INH) and PA acetylators. The phar-
macokinetics of PA and NAPA were analyzed with a computer
program (SAAM 23). Volume of distribution (Vd,,) and renal
clearance of PA were similar in normal subjects regardless of
acetylator phenotype. Nonrenal clearance was faster (383 vs. 244
mi/mm), and PA elimination half-life (t1/2) was shorter (2.6 vs. 3.5
hr) in fast acetylators. In the functionally anephric patients, Vd,,
was similar to that of normal subjects. Nonrenal clearance was
faster (117.5 vs. 93.5 mI/mm) and PA t1/ shorter (10.8 vs. 17.0 hr)
in fast than in slow acetylators. In these patients, acetylation
accounted for 56% of PA elimination, and NAPA concentrations
reached 0.8 g/m1 or more. The t1/z of NAPA in renal failure was
41.5 hr, in accord with predictions from studies in normal subjects,
assuming no impairment in nonrenal NAPA elimination. PA
metabolism, however, is severely impaired by renal failure, so PA
was prolonged to an unpredictably greater extent than would be
expected from studies in normal subjects.
Cinetique de Ia procainamide et de Ia N-acétyl-procainamide
dans l'insuffisance rénale. Quatre sujets normaux et quatre
malades dépourvus de fonction rénale ont recu 6,5 mg/kg de HCI-
procaInamide par voie intraveineuse. Les concentrations plasma-
tiques de procainamide (PA) et de son principal métabolite actif, Ic
N-acetyl-procaInamide (NAPA) ont été mesurées. Deux individus
de chaque groupe étaient des acetylateurs rapides de l'INH et de
PA. Les pharmacocinétiques de PA et de NAPA ont etC anaiysées
au moyen du programme SAAM 23. Le volume de distribution
(Vd,,) et Ia clearance rénale de PA sont semblables chez les
normaux quel que soit Ic phenotype d'acCtylation. La clearance
extra-rénale est plus grande (383 vs. 244 mI/mm) et la demie-vie
d'élimination de PA (t1/2) plus courte (2,6 vs. 3,5 hr) chez les
acetylateurs rapides. Chez les malades sans fonction rénale Vd,.
est semblable a celui des sujets normaux. La clearance extra-
rénale est plus grande (117,5 vs. 93,5 mI/mm) et le t de PA plus
court (10,8 vs. 17,0 hr) chez les acetylateurs rapides que chez les
lents. Chez les malades l'acétylation rend compte de SEP7o de
l'élimination de PA et les concentrations de NAPA atteignent 0,8
pg/mI ou plus. Le t'/2 de NAPA est de 41,5 hr dans l'insuffisance
rénale, cc qui est en accord avec l'extrapolation des résultats des
sujets normaux en postulant que l'élimination non rénale de
NAPA n'est pas modifiée. Le métabolisme de PA est cependant
gravement perturbé par l'insuffisance rénale, de telle sorte que Ic
t'/2 de PA est plus augmenté que l'extrapolation des résultats des
sujets normaux ne Ic laisse prévoir.
Dose alterations appropriate to various levels of
renal function can be estimated for drugs that depend
largely on renal function for elimination [1]. These
estimates are usually based on the renal elimination
rate and extent of metabolic transformation in sub-
jects with normal renal function. This approach
assumes that renal failure does not alter nonrenal
elimination mechanisms and does not take into con-
sideration possible accumulation of active metabo-
lites. Reidenberg has reviewed the effect of renal
disease on drug elimination and has found that meta-
bolic pathways involved in reduction, acetylation,
and hydrolysis may be impaired [2].
Approximately 50% ofan oral i.v. dose of procain-
amide (PA) is eliminated unchanged in the urine, and
the average half-life (t1/2) is three hours [3—6] (Dutch-
er, in preparation). On the basis of this alone, it
would be predicted that the t'/2 of PA in renal failure
would be approximately six hours. Gibson et al,
however, have found that the apparent t'/2 of PA
elimination in renal failure is variable and can range
from 5.3 to 20.7 hr after an oral dose [71. Since the
patients in that study were either physiologically or
surgically anephric, the data would suggest that the
metabolic transformation of PA is impaired by renal
failure.
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Dreyfuss et a! identified N-acetylprocainamide
(NAPA) as a metabolite of procainamide in 1972 [8].
Additional studies have shown that the acetylation of
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PA is under genetic control and that phenotypic
rapid acetylators of PA are also rapid acetylators of
isonicotinic acid hydrazide (INH) [5, 6, 9]. Since the
acetylation of INH has been reported to be slowed in
renal failure [10], it is possible that reduced acetyla-
tion of PA to NAPA in renal failure contributes to the
longer than expected t'/2 of PA in this disease state.
NAPA is an antiarrhythmically active metabolite
of PA [11—13]. Strong eta! has found that the t1/2 of
NAPA in normal subjects is 6.6 hr, and approximate-
ly 81% of an i.v. dose of NAPA is eliminated
unchanged in the urine [14]. The expected t1/2 of
NAPA in renal failure would be 35 hr.
The present study was undertaken to compare the
metabolic clearances of NAPA and PA in patients
with renal failure with the values obtained from stud-
ies in normal subjects. In addition, comparative data
is provided on PA pharmacokinetics in normal sub-
jects and in renal failure patients of known INH
acetylator phenotype.
Methods
After obtaining informed consent, four subjects
with normal renal function and four patients who
were anuric and either physiologically or surgically
anephric were studied. None had evidence of
congestive heart failure or liver disease. All patients
received 18 hr of hemodialysis per week and were
studied on a nondialysis day. On the day of the
study, baseline electrocardiogram and blood pres-
sure were taken prior to drug administration; these
parameters were monitored for two hours after the
drug administration. In normal subjects, a blank
urine was collected prior to the study. Thereafter, for
24 hr, the time and volume of each voiding was noted
and an aliquot was saved.
An indwelling butterfly needle with a heparin lock
was inserted into a peripheral vein, or an arterio-
venous fistula, and a control blood sample was tak-
en. Procainamide hydrochloride, 6.5 mg/kg of body
wt, was infused with a Harvard pump over a period
of 20 to 25 mm. At the conclusion of this infusion,
blood was sampled serially for 8 hr in normal sub-
jects and for 24 hr in the renal failure patients.
Renal function in normals was estimated by clear-
ance of endogenous creatinine. Acetylation pheno-
type was determined by estimating the t'/2 of isonico-
tinic acid hydrazide (INH) after an oral dose of 4 mg/
kg. Individuals with a INH t1/2 of less than 2 hr were
considered fast INH acetylators, and those with a t'/2
greater than 2.5 hr were considered slow [15].
Procainamide (PA) and N-acetylprocainamide
(NAPA) concentrations in plasma were determined
by the spectrophotofluorometric method of Matusik
and Gibson [16]. Urine levels of procainamide and
N-acetylprocainamide were determined by gas liquid
chromatography [5].
Concentrations and amounts of procainamide and
N-acetyprocainamide in figures and tables are
expressed as .tg/ml of base. Results in tables are
expressed as mean 1 SD.
Ph armacokinetic analysis. Plasma concentration
and cumulative urine excretion data were analyzed
with a computer program for multicompartmental
analysis (SAAM 23) [17]. This program was imple-
mented on a Control Data computer (digital comput-
er, model 6400, Control Data Corporation). As
shown in Figure 1, a two-compartment system was
used to model the distribution kinetics of PA. Even
though three-compartments can be distinguished
when PA is infused i.v. at at rapid rate [14, 18], when
administration of PA is slower it is possible to define
the parameters of only a two-compartment distribu-
tion model [19, 20]. Recent investigations in which
PA and NAPA labelled with radioactive carbon (13C-
NAPA) were simultaneously injected i.v. in normal
subjects have established that the distribution vol-
umes of these two compounds are identical [18]. For
this reason, a two-compartment distribution model
was also used to analyze the NAPA plasma concen-
tration data, and for each patient, the volumes of
these compartments were set equal to those of the
two-compartment PA model. The computer program
then iteratively adjusted the values of the distribution
PA
IIIEIIi
Metabolism
Renal
Excretion Unknown
Acetylation
NAPA
Metabolism
NAPA
4
Fig. 1. Multicompartmental model used to analyze the pharma-
cokinetics of procainamide (PA) and N-ace tylprocainamide
(NAPA) distribution and elimination. Abbreviations used are: Ve,
central compartment volume; Vi,, peripheral compartment vol-
ume; Q, intercompartmental clearances.
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volumes and rate constants of the model to minimize
the sum of squared deviations of the measured data
points from the theoretical plasma concentrations
calculated from the model parameters. Serum PA
concentrations in normal subjects and patients dif-
fered from theoretical values by 4.3% and 3.4%,
while NAPA concentrations in patients differed from
theoretical values by 5.9%. NAPA data for the first
90 mm after infusion was not used for analysis
because very high levels of PA relative to NAPA
have been shown to interfere with the spectrophoto-
fluorometric analysis of NAPA [161.
The t1/2 of PA and NAPA elimination was calculat-
ed from the results of the computer analysis, using
the equation:
t'/2 =
1.386
(k,, + k2, + k10) — [(k,2 + k2, + k,0)2 —4k21 k10]"2'
where k12 and k21 are the intercompartmental trans-
fer rate constants, and k,0 is the elimination rate
constant of the model [21]. Intercompartmental
clearances (Q) [22] were calculated from the product
of the appropriate intercompartmental transfer rate
constant and distribution volume according to the
equation:
Q = k,2V = k21V.
Elimination clearances were calculated from the
product of V, and the appropriate elimination rate
constant.
Since NAPA plasma concentrations could not be
measured in the normal subjects after a single PA
dose, PA elimination in these individuals could only
be subdivided into renal and nonrenal elimination.
Since less than 5% of an i.v. PA dose is eliminated in
feces (Dutcher, in preparation), it was presumed that
this nonrenal elimination represents PA metabolism.
In the patients with renal failure, it was possible to
calculate PA acetylation clearance, as well as to
estimate the extent of PA elimination by other path-
ways. For these analyses, NAPA plasma concentra-
tion data was multiplied by 0.85, the ratio of the mol
wt of PA/NAPA, to give its molar equivalent PA
concentration (PAequiv). This is necessary to main-
tain proper molar balance in calculations of NAPA
synthesis from PA. At steady state conditions, the
ratio of plasma NAPA and PA concentrations could
be estimated from the relationship:
Cacet [PA] = CNAPA [PAequjv] = 0.85 CNAPA [NAPA],
and therefore
[NAPA]
—
Cacet
[PA] 0.85 C NAPA
where Cacet is the acetylation clearance of PA, and
CNAPA is the elimination clearance of NAPA. Statisti-
cal comparisons are based on Student's t test with
statistical significance considered to be less than P =
0.05.
Results
Four subjects with normal renal function were
studied (Table 1, Fig. 2). All had normal renal func-
tion, as measured by creatinine clearance. Two were
fast INH acetylators, and two were slow, Pharma-
cokinetic parameters for PA are given in Table 2.
Volume of distribution (Vd,,) and peripheral com-
partment volume (V0) were relatively constant, 1.93
0.32 liter/kg of body wt and 1.20 0.13 liter/kg,
respectively, while central compartment volume (Va)
varied widely regardless of acetylator phenotype.
Total body clearance (C,) and nonrenal clearance
(C) of PA was less, and t'/z was longer in slow
acetylators (3.4 and 3.6 hr) than in fast acetylators
(2.5 and 2.8 hr). Renal PA clearance (Cr) was essen-
tially identical in all four subjects, as was creatinine
clearance. The cumulative amount of unchanged PA
recovered in the urine of the slow acetylators was
more (255 mg and 275 mg) than in the fast acetylators
(250 mg and 200 mg). Cumulative elimination of
NAPA was greater in the fast acetylators (37.14 mg
and 57.41 mg) than in the slow (25.11 mg and 26.12
mg).
After the single PA dose, NAPA concentrations in
the serum of normal subjects were below the lower
limit of detection of the analytical method (0.10 sg/
Table 1. Data on normal subjects and on patients with end
stage renal failur&'
Body wt
kg Sex
Age
yrs
INH tV2
hr
C,,
mi/mm
Normal subjects
1 86.4 M 34 3.6 115
2 87.5 M 36 3.7 120
3 81.8 M 32 1.6 125
4 85.0 M 33 1.3 110
Mean 85.2 33.7
1.7
117.5
Patients with end-
stage renal
failure
1 72.5 M 51 1.6 SAN
2 80.5 M 56 1.2 PAN
3 78.0 M 56 3.8 PAN
4 59.0 F 45 3.0 SAN
Mean 72.5 52.0
a Abbreviations used are: INH, isonicotinic acid hydrazide;
Ccr, creatinine clearance; SAN, surgically anephric; PAN,
physiologically anephric.
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Fig. 2. Pharmacokinetic analysis of plasma procainamide (PA) concentrations (circles) and
cumulative PA excretion in urine (squares) after administration of a single i.v. PA dose to four
normal subjects. The solid lines are a least-squares fit of the data points.
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ml), so NAPA pharmacokinetics could not be inves-
tigated in these individuals.
Four patients with end-stage renal failure were
studied (Table 1, Fig. 3). Two were fast INH acetyla-
tors and two were slow. Pharmacokinetic parameters
for PA in renal failure are given in Table 2. The Vd0
of 1.67 liter/kg was slightly less than in normals, but
not significantly so (P > 0.05). The same is true of V
and V. C and Car, however, were both significantly
less than their respective values in normals (P <
0.01), and since renal clearance (Cr) was zero, C
equaled Cur.
The t'/z of PA in the patients with renal failure was
much greater than in the normal subjects, 13.9 4.5
hr compared to 3.1 0.5 hr. Patients with renal
failure who were fast acetylators had a shorter PA t1/z
(11.5 and 10.1 hr) than did the slow acetylators (20.2
and 13.8). Nonrenal clearance, or metabolic transfor-
mation rate, was considerably reduced in the slow
acetylators, 88 and 99 mI/mm, compared to 121 and
114 mllmin in the fast acetylators.
Unlike subjects with normal renal function, NAPA
was detectable in the serum of all patients with renal
failure after a single PA dose (Fig. 3).
Subject 2
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Table 2. Pharmacokinetics of procainamide (PA) administered to normal subjects and to patients with end-stage renal failurr'
V. V V Q C Cnr Cr t'/2
liters liter/kg liters liter/kg liters liter/kg liter/mm mi/mimi in//rn in rn//rn in Iii
Normal subjects
1 39.8 0.46 109.4 1.27 149.2 1.73 3.86 555 241 314 3.4
2 72.6 1.21 113.6 1.30 186.2 2.13 3.19 645 246 399 3.6
3 103.5 1.27 83.1 1.02 186.6 2.28 2.91 934 398 536 2.5
4 32.8 0.39 104.1 1.22 136.9 1.61 2.19 685 368 316 2.7
Mean 62.1
32.6
0.83
0.47
102.6
13.5
1.20
0.13
164.7
25.5
1.93
0.32
3.03
0.69
705
162
313
81
391 3.1
104 0.5
Patients with end-
stage renal
failure
I 41.2 0.57 69.7 0.96 110.9 1.53 1.95 114 114 0 11.5
2 34.2 0.42 69.3 0.86 103.5 1.29 1.88 121 121 0 10.1
3 52.2 0.67 96.8 1.24 149.0 1.91 1.38 88 88 0 20.2
4 51.1 0.87 63.5 1.08 114.6 1.94 1.02 99 99 0 13.8
Mean 44.7
8.6
0.63
0.19
74.8
14.9
1.04
0.16
119.5
20.2
1.67
0.31
1.56
0.44
106
15
106
15
0 13.9
4.5
volume of distribution: Q,Abbreviations used are: Ve, central compartment volume; V, peripheral compartment volurne;Vd,,,
intercompartmental clearances; C1, total body clearance; Cur. nonrenal clearance: Cr, renal clearance.
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Fig. 3. Pharrnacokinetic analysis ofplasrna procainarnide (PA) (circles) and N-acety!procainarnide (NAPA) (triangles) concentrations after
adrninistration of a single iv. PA dose tofourfunctionally or surgically anephric patients. In patient 4, the point shown as an open triangle
was considered to be in error and was omitted from the least-squares analysis of the data.
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Table 3. Pharmacokinetics of N-acetylprocainamide administered to patients with end-stage renal failurea
Procainamide acetylation
Q C
Predicted
steady-state t1/2Clearance Total
Patients mi/mm elimination, % liter/mm mi/mm NAPA/PA hr
I 79.2 70 0.223 44.6 1.8 31.1
2 61.2 50 0.299 24.2 2.5 49.8
3 35.5 41 7.123 39.6 0.9 43.6
4 63.6 64 0.380 32.9 1.9 41.3
Mean 59.9
18.1
56.3
13.2
2.01
3.41
35.3
8.8
1.8
0.7
41.5
7.8
a Abbreviations used are: Q, intercompartmental clearances; C, total body clearance.
Calculated parameters of NAPA pharmacokinet-
ics are presented in Table 3. Acetylation clearance of
PA was 59.9 18.1 ml/min and accounted for 56.3
13.2% of the total elimination of PA.
Predicted steady-state ratio of NAPA to PA in
serum was higher in fast acetylators (1.8 and 2.5)
than in slow acetylators (0.9 and 1.9). Total clear-
ance of NAPA was 35.3 8.8 mi/mm, significantly
slower than the total clearance of PA in the same
patients. Estimated t'/2 of NAPA in these subjects
was 41.5 7.8 hr.
Discussion
The results of the present study indicate that the
t1/2 of PA in renal failure is unpredictably prolonged
because of altered metabolic transformation.
While the volume of distribution (Vd ) ofPA is not
affected by end-stage renal failure, total clearance
(Ci) is markedly reduced and is equal to nonrenal
clearance (Table 2). In the presence of normal renal
function, the elimination rate constant (k0) equals the
sum of the renal excretion rate constant (kr) plus all
nonrenal excretion rate constants (knr). In normal
subjects, kr and knr for PA are almost identical (Table
2). In subjects with normal renal function, many
observers have found a PA t'/z of three hours and
have recovered approximately 50% of the dose
unchanged in the urine [3, 5, 18—22]. In renal failure,
if knr is unaltered, the expected ke of PA would be
one-half that in normals, and the t1/2 would be six
hours. As shown in Table 2, however, knr in renal
failure is one-third that in normals. Since nonrenal
elimination represents the only elimination route of
PA in the anephric patient, it must be concluded that
this route is severely impaired.
Nonrenal clearance of PA represents acetylation
and possibly other metabolic pathways, since Giardi-
na and associates have incompletely identified two
other PA metabolites in the urine of subjects receiv-
ing PA orally [23]. PA is ace tylated by N-acetyl-
transferase, the same enzyme responsible for the
acetylation of isonicotinic acid hydrazide (INH) [5,
6, 91. Some investigators have reported that acetyla-
tion of INH is normal in renal failure [24, 25], while
others have found it to be impaired [10]. In the
present study, fast INH acetylators have a faster
nonrenal (metabolic) clearance of PA than do slow
acetylators (Table 2), shorter PA t1/z, and higher
serum concentrations of NAPA (Fig. 3). Half-life
changes, however, are not as accurate a reflection of
altered drug elimination as are clearance changes,
since t'/2, as opposed to clearance, is not a primary
pharmacokinetic parameter and is influenced by dis-
tribution volume as well as clearance rates [22]. As
shown in Table 2, nonrenal elimination of PA is
markedly decreased in renal failure and appears to be
even less in slow than in rapid acetylators. Since
acetylation accounts for 56% of the total elimination
of PA in renal failure (Table 3), it is likely that both
this route and other pathways accounting for the
remaining 44% are slowed.
Pharmacokinetic parameters of PA in normal sub-
jects agree with values previously reported by others
[3, 201. Renal clearance of PA was similar to that
observed by Koch-Weser (179—309 ml/min) [3] and
Galeazzi et al (345 mi/mm) [261, but much higher
than that reported by Reidenberg et al [91. Although
the actual creatinine clearance of Reidenberg's
patients was not directly stated, the mean renal
clearance of PA in slow acetylators was 145 mI/mm
with a PA to creatinine clearance ratio of 2.3, indicat-
ing that the mean creatinine clearance in slow acety-
lators was 63 mI/mm. In rapid acetylators, the ratio
was 2.1 and creatinine clearance was 64 mI/mm.
The mean t'/2 of PA in normal subjects is similar to
the V!2 found by others [3,4, 6, 8, 19—21, 26, 28]. It
appears, however, that fast acetylators have a short-
er t1/2 of PA than do slow acetylators. This has been
reported previously [5, 261 and is expected, since
nonrenal clearance is faster in the fast acetylators
(383 ml/min) than in the slow (234 mi/mm) (Table 2).
The differences of urinary excretion of PA and
NAPA also agree with previous reports [5, 261.
Estimation of the parameters of NAPA pharma-
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cokinetics (Table 3) is based upon the assumption
that the Vd of NAPA is equal to that of PA, as has
been found in patients with normal renal function
[181. As can be seen in Table 3, the C of NAPA is
similar in all subjects, and, consequently, the pre-
dicted tY2 is similar. Strong et al have found that the
t'/2 of i.v. administered NAPA is 6.6 hr and that 81 to
85% of the dose is eliminated unchanged in the urine
[14]. From this data, the predicted t'/2 of NAPA in
renal failure would be 35 to 44 hr, in close agreement
with its observed value of 41 hr. Therefore, the
nonrenal elimination of NAPA, which only accounts
for 19% of the dose, is little affected by renal failure.
Absence of renal function leads to NAPA accumu-
lation in serum, as seen in the four subjects in Figure
3. Predicted steady-state ratio of NAPA to PA in
end-stage renal failure is 1.8 overall, but is higher in
fast acetylators, as are serum NAPA concentrations
(Table 3). Even this predicted ratio is considerably
less than the ratio of about 5, observed after chronic
administration of PA to a single patient with end-
stage renal disease [29]. It can be expected, then,
that NAPA accumulation will be even greater in
some renal failure patients than in the four patients
presented here.
The use of PA in renal failure is complicated by the
unpredictable prolongation of PA t1!a and accumula-
tion of NAPA. NAPA, an active antiarrhythmic drug
[11—131, has been found to persist in the serum of an
anephric patient for over 123 hr after a single oral
dose of PA [30]. If a renal failure patient is to be
treated with PA, the serum concentrations of both
PA and NAPA must be monitored. Goldstein has
shown that if a drug is given without a loading dose it
will take 3.3 half-lives to reach 90% of the eventual
steady-state level [31]. For PA, this would be 48 hr
on the average, but since the t'/2 of NAPA is 41 hr, its
steady-state levels would not be reached for 137 hr.
If therapy were effective, the arrhythmia would have
been abolished long before NAPA reached steady-
state levels and perhaps even before PA levels have
stabilized. In this setting continued accumulation of
these compounds may result in clinical toxicity that
represents a combination of PA and NAPA effects.
Although our conclusions are based on only a
small number of patients, it appears that while V
of PA is unaltered by renal failure, the tV2 is unpre-
dictably prolonged due to alterations in metabolic
transformation, so a prior estimation of correct pro-
cainamide dosage is impossible. In contrast, the rate
of nonrenal elimination of NAPA is unaffected by
renal failure, and NAPA elimination t'/2 appears to be
well correlated with creatinine in patients with mod-
erately impaired renal function [13]. NAPA would,
therefore, be preferable to PA for the treatment of
ventricular arrhythmias in renal failure patients
because dose modification could be made more relia-
bly. In addition, NAPA may be less likely than PA to
produce a lupus-like syndrome [6, 9, 11, 12]. If PA
must be used in dialysis patients, dialysis readily
removes not only PA but also NAPA [7, 29, 30, 32,
33] and can be used to treat PA toxicity [33].
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